The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Oral curcumin for the prevention of vincristine-induced neuropathy in pediatric ALL: Phase III trial results
Vincristine, a vinca alkaloid used in the treatment of ALL, is known to cause peripheral neuropathy.1 Evidence shows curcumin can effectively prevent the development of several neurological conditions.1 Results from a single center phase III clinical trial (IRCT20201107049296N3) evaluating the effectiveness of oral curcumin in preventing the development of vincristine-induced peripheral neuropathy (VIPN) in pediatric patients with ALL were published by Eghbali et al.1 in BMC Cancer. Eligible patients were randomized to receive curcumin (n = 74) or placebo (n = 74). The primary endpoint was the occurrence of VIPN.1
|
Key learnings |
| Among 141 evaluable patients, VIPN occurred in 42.6% vs 66.4% of patients based on TNS-PV, 62.1% vs 82.5% of patients based on NCS, and 17.0% vs 54.0% of patients based on EMG in the curcumin vs placebo group, respectively. |
| Overall, patients in the curcumin group experienced a lower incidence of VIPN vs those in the placebo group (39.4% vs 70.0%; p < 0.001). |
| The frequency of motor nerve (p = 0.012) and sensory nerve (p = 0.440) abnormalities were lower in the curcumin vs placebo group. |
| These findings show that curcumin improved VIPN, reduced motor nerve abnormalities, and was effective in preventing the development of VIPN in pediatric patients with ALL. Curcumin may therefore represent a promising adjunct therapy for mitigating chemotherapy induced neuropathy. |
Abbreviations: ALL, acute lymphoblastic leukemia; EMG, electromyography; NCS, nerve conduction study; TNS-PV, Total Neuropathy Score Pediatric Vincristine; VIPN, vincristine-induced peripheral neuropathy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
